Monarch Medical Technologies to Participate in the American Diabetes Association’s 79th Scientific Sessions and DiabetesMine D-Data ExChange

CHARLOTTE, N.C.--()--Monarch Medical Technologies, the leader in precision insulin dosing technology for optimized glycemic management, today announced it will be participating in two upcoming diabetes industry events, the DiabetesMine D-Data ExChange on June 7th, 2019 and the American Diabetes Association’s 79th Scientific Sessions on June 7-11, 2019 in San Francisco, CA.

During the DiabetesMine D-Data ExChange, Dr. Patrick Burgess, the inventor of Monarch’s EndoTool® Glucose Management System, will be demonstrating the FDA-cleared, patented software showcasing its personalized dosing recommendations for intravenous and subcutaneous insulin therapy.

On June 9th at 12 PM PST, Dr. Burgess will also be presenting clinical research in a poster presentation at the American Diabetes Association’s 79th Scientific Sessions. The poster, “The Impact of Late Glucose Checks on Hypoglycemia Incidence,” will be located at 392-P in category 01 Complications–Hypoglycemia. Monarch will also be exhibiting at booth #738.

“In order to deliver the best care for patients and achieve optimal clinical and financial outcomes in the acute-care setting, we must manage hyperglycemia and avoid hypoglycemia. To do that, advanced algorithms focused on safety and control are necessary,” said Dr. Burgess. “We look forward to taking part in these industry events to showcase Monarch’s solution and clinical research and to continuing the movement to advance inpatient glycemic management.”

About Monarch Medical Technologies

Monarch Medical Technologies is the leading provider of electronic systems for inpatient glycemic management. Monarch’s EndoTool® Glucose Management System offers personalized dosing recommendations for intravenous and subcutaneous insulin therapy. As a Class II FDA-cleared, patented software suite, EndoTool has been chosen by more than 300 hospitals to provide unsurpassed patient-specific glycemic control across a broad population of patients, and ultimately deliver better, safer care. For more information, please visit monarchmedtech.com.

Contacts

Flannery Nangle
Monarch Medical Technologies
315-406-5495
flannery.nangle@monarchmedtech.com

Contacts

Flannery Nangle
Monarch Medical Technologies
315-406-5495
flannery.nangle@monarchmedtech.com